Dopamine is a neurotransmitter involved in the reward pathways in the brain, and its decreased activity has been associated with diseases such as parkinson’s disease and attention-deficit/hyperactivity disorder (adhd). which of the following drugs is not a likely candidate to treat these diseases?

a. methylphenidate, a dopamine reuptake inhibitor

b. amphetamine, a dopamine-releasing agent that triggers the release of dopamine into the synaptic cleft

c. carbidopa, which enhances the availability of the dopamine synthesis precursors in the brain

d. forskolin, a sensitizer of dopamine receptors

e. chlorpromazine, a dopamine antagonist that binds to and inhibits dopamine receptors